Epigral Limited — Earnings Release 2026

Aug 2, 2025

==> picture [128 x 18] intentionally omitted <==

02.08.2025

To, National Stock Exchange of India Limited “Exchange Plaza”, Bandra-Kurla Complex, Bandra (East) Mumbai 400 051

BSE Limited Floor- 25, P J Tower, Dalal Street, Mumbai 400 001

SYMBOL:- EPIGRAL

Scrip Code: 543332

Dear Sirs,

Sub.: Press Release on Un-Audited Financial Results – Q1 FY26 Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release on Un-Audited Financial Results – Q1 FY26.

The said Press Release is also available at www.epigral.com in the Investor Relations section.

This is for information and records.

Thanking you,

Yours faithfully,

For Epigral Limited

(formerly known as ‘Meghmani Finechem Limited’)

GAURANG Digitally signed by GAURANG GHANSHYAM GHANSHYAM TRIVEDI TRIVEDI Date: 2025.08.02 13:21:26 +05'30'

Gaurang Trivedi Company Secretary & Compliance Officer M. No. 22307

==> picture [346 x 76] intentionally omitted <==

==> picture [10 x 116] intentionally omitted <==

==> picture [183 x 33] intentionally omitted <==

Press Release

Epigral Limited’s Q1FY26 Revenue stood at ₹ 615 Crore

August 2, 2025: Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter ended June 30, 2025. The company posted a revenue of ₹ 615 Crore for the quarter ended June 30[th] , 2025 as against ₹ 654 Crore recorded in Q1YF25. During the quarter under review, PAT stood at ₹ 160 Crore (includes decrease in deferred tax liability of ₹ 81 Cr) compared to ₹ 86 Crore in Q1FY25.

Commenting on the results Mr. Maulik Patel; Chairman and Managing Director – Epigral said: “Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26.

Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget. We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex.

We are working on the new chemistry at our new land parcel. This new chemistry project will be on similar lines of our earlier projects, i.e. import substitution products where demand is expected to grow in double digits and where we can generate good ROCE.

We continue our journey to move forward in our direction of scalability with profitability, strengthening our integration and creating value for our stakeholders.” Mr Patel added.

The key performance highlights:

Q1FY26 Operational and Financial Highlights:

• Plant utilization stood at 73%

• ROCE grew to 24% as on 30[th] June 2025 vs 21% as on 30[th] June 2024 due to improved earnings

• Net Debt/EBITDA reduced to 0.6x as on 30[th] June 2025 vs 1.6x as on 30[th] June 2024 on account of improvement in EBITDA and reduction in Net Debt

• YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivatives & Specialty business stood at 50%

• EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on efficiency and product mix

• PAT stood at ₹ 160 Cr, however PAT excluding deferred tax liability benefit stood at ₹ 79 Cr as against ₹ 86 Crore in Q1FY25

Strategic Updates:

• Epigral Capex plans are moving as per schedule and are expected to get commissioned within the timeline and budget

  • CPVC Resin capacity will reach to 1,50,000 TPA, by adding additional 75,000 TPA

  • Epichlorohydrin capacity will reach to 1,00,000 TPA, by adding additional 50,000 TPA

  • Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW, by adding additional 19.80 MW

• Epigral commissioned India’s 1[st] Chlorotoluenes Value Chain plant in March 2025.

About Epigral Limited

Epigral Limited (Epigral), formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure. In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

Epigral is strengthening its position in the specialty chemical business by enhancing its capacity its CPVC and ECH capacity, venturing into the Chlorotoluenes value chain and dedicated R&D centre. The company is focused on sustainable value creation for all its stakeholders.

Through integral collaborations and exceptional solutions, Epigral strives to enhance value and exceed expectations, leaving an indelible mark on stakeholders and the industry.